Bacterial mitigation strategies: impact of pathogen reduction and large-volume sampling on platelet productivity

Garcia, Ron; Razatos, Anna

doi:10.21037/aob-21-19

Cited by 3 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even blood centers that have successfully recruited younger donors into their apheresis programs still rely on older donors to contribute the largest volume of apheresis platelet units (Lasky, Singh, & Young, 2023). US blood centers are producing fewer apheresis platelets after implementation of the US Food and Drug Administration (FDA)-mandated bacterial mitigation strategies (Garcia & Razatos, 2021;Pandey et al, 2021;US Food and Drug Administration, 2020). Mitigation strategies require either larger volumes to be sampled for bacterial screening or pathogen reduction, both of which result in fewer platelets available for transfusion (Garcia & Razatos, 2021;Benjamin, Katz, Gammon, Stramer, & Quinley, 2019).…”

Section: Introductionmentioning

confidence: 99%

State of affairs: the US platelet supply and the role of whole blood–derived platelets

Razatos,

King

2024

JBSE

Self Cite

View full text Add to dashboard Cite

PurposeThe US platelet supply is almost exclusively dependent on apheresis donors who are “aging out.” As a result, blood centers and hospitals have been experiencing spot shortages and have resorted to transfusing low-dose platelets. This paper explores using whole blood–derived platelets (WB-PLTs) to supplement the apheresis platelet (APH-PLT) supply.Design/methodology/approachThis paper reviews the history leading to the current state of the US platelet supply and includes the impact of recent events such as the COVID-19 pandemic and the implementation of the US Food and Drug Administration (FDA)-mandated bacterial mitigation strategies.FindingsWB-PLTs represent a viable source of platelets that can be used to supplement the APH-PLT supply. Whole blood automation represents a new methodology to more easily prepare WB-PLTs. Advances in donor testing and screening as well as pre-storage leukoreduction have improved the safety of WB-PLTs to the same level as APH-PLTs. Blood services in the US and abroad transfuse WB-PLTs interchangeably in all patient populations.Originality/valueThis paper highlights how the US blood industry is essentially “sole-sourced” in terms of APH-PLTs. In this post-COVID-19 period, when most industries are building redundancies in their supply chains, blood centers should consider WB-PLTs as an additional source of platelets to bolster the US platelet supply.

show abstract

Section: Introductionmentioning

confidence: 99%

State of affairs: the US platelet supply and the role of whole blood–derived platelets

Razatos,

King

2024

JBSE

Self Cite

View full text Add to dashboard Cite

show abstract

“…Transfusion-transmitted bacterial infections (TTBI) and associated transfusion septic reactions are currently the leading cause of transfusion-related morbidity and mortality globally [1,[3][4][5][6][7][8][9], although they remain widely under-recognized and under-reported, including in Latin America [1]. Risks associated with viral agents have decreased over the past decades [10]; however, new challenges have arisen with changes in sexual behaviors, social issues, human migrations, and climate change, and vary depending on geographic location.…”

Section: Introductionmentioning

confidence: 99%

“…The main anticipated disadvantage of PR is a cost increase in blood component production; however, the cost of implementation can be offset by gains in efficiency through streamlined production methods as well as the discontinuation of procedures such as irradiation and the replacement of specific screening strategies. The benefits of PRT and its added value to blood safety have been recognized by blood transfusion services and hospitals in several countries, including some LMICs [3,[28][29][30].…”

Section: Introductionmentioning

confidence: 99%

The 4-Year Experience with Implementation and Routine Use of Pathogen Reduction in a Brazilian Hospital

et al. 2021

View full text Add to dashboard Cite

(1) Background: We reviewed the logistics of the implementation of pathogen reduction (PR) using the INTERCEPT Blood System™ for platelets and the experience with routine use and clinical outcomes in the patient population at the Sírio-Libanês Hospital of São Paulo, Brazil. (2) Methods: Platelet concentrate (PC), including pathogen reduced (PR-PC) production, inventory management, discard rates, blood utilization, and clinical outcomes were analyzed over the 40 months before and after PR implementation. Age distribution and wastage rates were compared over the 10 months before and after approval for PR-PC to be stored for up to seven days. (3) Results: A 100% PR-PC inventory was achieved by increasing double apheresis collections and production of double doses using pools of two single apheresis units. Discard rates decreased from 6% to 3% after PR implementation and further decreased to 1.2% after seven-day storage extension for PR-PCs. The blood utilization remained stable, with no increase in component utilization. A significant decrease in adverse transfusion events was observed after the PR implementation. (4) Conclusion: Our experience demonstrates the feasibility for Brazilian blood centers to achieve a 100% PR-PC inventory. All patients at our hospital received PR-PC and showed no increase in blood component utilization and decreased rates of adverse transfusion reactions.

show abstract

Section: Introductionmentioning

confidence: 99%

“…The main anticipated disadvantage of PI is a cost increase in blood component production; however, the cost of implementation can be offset by gains in efficiency through streamlined production methods as well as the discontinuation of procedures such as irradiation and the replacement of specific screening strategies. The benefits of PRT and its added value to blood safety have been recognized by blood transfusion services and hospitals in several countries, including some LMICs [3,[28][29][30].…”

Section: Introductionmentioning

confidence: 99%

The 4-Year Experience with Implementation and Routine Use of Pathogen Inactivation in a Brazilian Hospital

Fachini¹,

Fontão-Wendel²,

Achkar³

et al. 2021

Preprint

View full text Add to dashboard Cite

(1) Background: We reviewed the logistics of the implementation of pathogen inactivation (PI) using the INTERCEPT Blood System™ for platelets and the experience with routine use and clinical outcomes in the patient population at the Sírio-Libanês Hospital of São Paulo, Brazil. (2) Methods: Platelet concentrate (PC), including pathogen reduced (PR-PC) production, inventory management, discard rates, blood utilization, and clinical outcomes were analyzed over the 40 months before and after PI implementation. Age distribution and wastage rates were compared over the 10 months before and after approval for PR-PC to be stored for up to 7 days. (3) Results: A 100% PR-PC inventory was achieved by increasing double apheresis collections and production of double doses using pools of two single apheresis units. Discard rates decreased from 6% to 3% after PI implementation and further decreased to 1.2% after 7-day storage extension for PR-PCs. The blood utilization remained stable, with no increase in component utilization. A significant decrease in adverse transfusion events was observed after the PI implementation. (4) Conclusion: Our experience demonstrates the feasibility for Brazilian blood centers to achieve a 100% PR-PC inventory. All patients at our hospital received PR-PC and showed no increase in blood component utilization and decreased rates of adverse transfusion reactions.

show abstract

Bacterial mitigation strategies: impact of pathogen reduction and large-volume sampling on platelet productivity

Cited by 3 publications

References 8 publications

State of affairs: the US platelet supply and the role of whole blood–derived platelets

State of affairs: the US platelet supply and the role of whole blood–derived platelets

The 4-Year Experience with Implementation and Routine Use of Pathogen Reduction in a Brazilian Hospital

The 4-Year Experience with Implementation and Routine Use of Pathogen Inactivation in a Brazilian Hospital

Contact Info

Product

Resources

About